The HPTN will showcase key data and valuable insights during the upcoming AIDS 2024 conference.

We invite you to attend and engage in several activities, including symposia and posters on the use and implementation of long-acting cabotegravir for pre-exposure prophylaxis (PrEP), the effectiveness of PrEP in different populations, and notable innovative strategies used in HIV prevention. You can mark these sessions in your conference schedule.

Follow the HPTN on social media (@HIVptn) for highlights. We look forward to seeing you there!

 

Join the HPTN at AIDS 2024:

 

 

 

Global Village

We are collaborating with the HIV Vaccine Trials Network to host a Networking Zone in the Global Village:

Help End HIV: Clinical Trials for HIV Prevention
July 21-26, 10:00 a.m. - 4:00 p.m. CEST
Booth #: HT06

Visit throughout the conference to hear more about our research priorities and prevention successes. Presentations will also be offered in Spanish.

 

Presentations

Oral Abstract Session
Advanced HIV Disease: Hiding in Plain Sight
July 23, 3:00 p.m. - 4:00 p.m. CEST
Room 14b/Channel 3

• Performance characteristics of HIV RNA screening with long-acting injectable cabotegravir (CAB-LA) pre-exposure prophylaxis (PrEP) in the multicenter global HIV Prevention Trials Network 083 (HPTN 083) Study | Raphael Landovitz

 

Symposium
SY25 Use of long-acting injectable cabotegravir in pregnant and lactating people 
July 25, 10:30 a.m. - 11:30 a.m. CEST
Room 13a/Channel 7

• Safety of injectable cabotegravir in pregnancy: Results from HPTN 084 | Sinead Delany-Moretlwe
• Pharmacokinetics and dosing requirements for injectable cabotegravir during pregnancy: Results from HPTN 084 | Mark Marzinke

 

Posters 

• Association between substance use and PrEP adherence among AGYW enrolled in an HIV prevention study (HPTN 082) in Southern Africa 

• Pre-Exposure Prophylaxis product choice of participants in HPTN 083 

• A community-academic partnership to empower Black MSM for economic development, advocacy, and HIV prevention research: HPTN 096 

• Changes in sexual behavior among adolescent girls receiving long-acting injectable cabotegravir for HIV prevention: the HPTN 084-01 study 

• What factors influence whether stigmatizing attitudes change over time? An analysis of HIV stigma attitudes and perceptions among community members participating in the HPTN 071 (PopART) trial 

• HPTN 094: Engaging Key Community Stakeholders in Preparation for Mobile Clinics Providing Integrated Health Services (Medication for Opioid Use Disorder and HIV Treatment/Prevention Services) for People Who Inject Drugs (PWID) 

• Understanding Parental Motivations and Decision-Making for Adolescent Girls’ Participation in the Long-Acting Cabotegravir (CAB-LA) Trial – Insights from HPTN 084-1 

• First-in-human evaluation of the safety, pharmacokinetics, and neutralization activity of PGDM1400-LS, a V2 glycan-specific HIV-1 broadly neutralizing antibody, infused intravenously or subcutaneously in people without HIV-1 (HVTN140/HPTN101 Part A) 

• A first-in-human phase 1 trial of PGT121.414.LS administered alone and in combination with VRC07-523LS: safety, tolerability, pharmacokinetics, and neutralization activity (HVTN 136/HPTN 092) 

• Enhancing Inclusivity: Examining the Global Impact of Cultural Competency on Clinical Trial Recruitment in HPTN – 10 Year Update 

 

For a complete list of activities, browse the conference program.

 

Want to attend?